Ulka Vaishampayan MD

Ulka Vaishampayan, MD, is a Professor of Internal Medicine, Leader of the Translational and Clinical Research Program and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center, Ann Arbor MI. She serves as the Chair of the SWOG Advanced Renal Committee, is a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, and her research focuses on translational drug development. She is PI of the Dept of Defense Kidney Cancer Consortium site award and a DOD clinical trial award and is a current recipient of the Prostate cancer Foundation Tactical and Challenge Awards. She is PI of the national phase III SWOG1931/PROBE trial in kidney cancer. She is leading a “Women in RCC” initiative. She has completed leadership training and has acquired the prestigious Fellowship of the Advisory Board (FAB). Dr. Vaishampayan has >250 publications and is editor -in-chief of Journal of Kidney Cancer VHL (JKCVHL). She is a peer reviewer for multiple journals such as Lancet, Clin Cancer Res and J Clin Oncol and a grant reviewer for Dept of Defense, AACR, SITC and Kidney Cancer Association and KCCure. She has given multiple podium presentations at ASCO, ESMO and SITC. She has served as track leader for the Education committee for ASCO annual meeting, and as a Scientific review committee for ASCO. She has mentored trainees in the US and around the globe via ASCO mentorship program for the past 5 years. She is leader of the “Women in Oncology” community within ASCO and is serving currently as a member on the Genitourinary Cancer Guideline Advisory Group. She combines administrative duties with a busy clinical practice and research.